Opinion

Congress could undermine NC’s biotech boom

Patients in countries with government price-setting systems often wait longer for access to new medicines and have access to less than half as many treatments for complex conditions like cancer, neurological disorders, autoimmune diseases, blood disorders, and rare diseases.

Laura Gunter

Help Support Non-profit Journalism & Donate Today